Autopsy report · NCT03114319

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

“Business reasons and not due to any safety concerns”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 8 years 1 month before it stopped.
• 227 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC); KRAS G12-mutant NSCLC; Esophageal Squamous Cell Cancer (SCC); Head/Neck SCC; Melanoma; Advanced Gastrointestinal Stromal Tumors (GIST)

Interventions

TNO155; TNO155 in combination with EGF816 (nazartinib)

Participants

227

Sites

18

Countries

Canada, Italy, Japan, Netherlands, Singapore, South Korea, Spain, Taiwan, United States

Trials that died the same way

• Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
  “Business reasons and not based on any safety concerns.” (94% match in meaning)
• Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
  “Business reasons not related to safety” (89% match in meaning)
• A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
  “business decision, not safety reasons.” (84% match in meaning)
• An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension
  “Business reasons unrelated to product safety” (77% match in meaning)
• AGN-242428 in the Treatment of Plaque Psoriasis
  “safety reason” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.